Search
Press "Enter" to search and "ESC" to close.

What is the RSV vaccine for pregnant women?

2023-09-01T16:02:16+00:00
Getting your Trinity Audio player ready...
Suscríbete a Nuestro Boletín
Recibe por email las noticias más destacadas
RSV vaccine pregnant women, pregnancy, respiratory syncytial virus, FDA, MundoNOW vacuna VSR mujeres embarazadas, embarazo, virus sincitial respiratorio, FDA, MundoNOW
RSV vaccine for pregnant women (Photo: Shutterstock)
  • FDA approves first RSV vaccine for pregnant women.
  • Safeguarding infants from this disease.
  • RSV can be deadly for children.

On August 21, it was announced that the Food and Drug Administration (FDA) has officially approved the first vaccine targeting the respiratory syncytial virus (RSV) for pregnant women.

This development equips the United States with a new defense mechanism to protect infants from this highly contagious virus.

Today, RSV ranks as the primary cause of respiratory tract infections among young children.

It has the potential to be particularly dangerous for infants under six months old and is the leading factor contributing to pediatric hospital admissions in the United States.

The impact of RSV on children’s health: Disturbing statistics

Infant hospitalization, USA, United States, babies, MundoNOW
RSV Vaccine for pregnant women / PHOTO: Shutterstock

As if was not concerning enough, the respiratory syncytial virus (RSV) has been associated with roughly half a million visits to emergency rooms.

To clarify, this translates to nearly 100,000 hospitalizations and approximately 300 fatalities among young children in the United States.

Marketed under the brand name Abrysvo, this vaccine has been approved for administration between the 32nd and 36th weeks of pregnancy.

Its purpose is to shield newborns up to six months of age from the adverse effects of RSV.

Guidelines and alternatives to protect babies

RSV vaccine for pregnant women, CDC, October 2023, recommendations, MundoNOW
PHOTO: Shutterstock

The Centers for Disease Control and Prevention (CDC) is set to convene a meeting in October with a particular agenda.

The objective? To formulate recommendations pertaining to the administration of Abrysvo, which could become available in a matter of months.

Notably, in mid-July, the FDA also granted approval for a long-lasting, single-dose monoclonal antibody to prevent RSV in infants.

Marketed as Beyfortus, this antibody targets newborns and children up to two years of age.

Pregnant women have options for preventing RSV

approval, maternal vaccine, disease, children, MundoNOW
RSV vaccine for pregnant women / PHOTO: Shutterstock

The approval of the RSV vaccine for pregnant women is indeed a significant event.

Expectant mothers now have options when it comes to preventing RSV in infants — the maternal vaccine and the monoclonal antibody.

The protein-based vaccine operates similarly to the Tdap vaccine against pertussis, or whooping cough.

Tdap is administered between the 27th and 36th weeks of pregnancy to provide immunity against tetanus, diphtheria, and whooping cough.

RSV vaccine for pregnant women: Evidence of efficacy and safety

RSV vaccine, clinical trial, placebo, diseases, MundoNOW
PHOTO: Shutterstock

The FDA’s approval was based on data from clinical trials encompassing over 7,000 participants across 18 countries who were administered the RSV vaccine.

In this rigorous trial, the RSV vaccine for pregnant women showed an efficacy rate of 82 percent in preventing severe lower respiratory tract infections.

The vaccine will carry a notification regarding a slight increase, less than 1 percent, in preterm births among the group that received the vaccine.

Presently, there is no established connection between the vaccine and preterm birth, and the observed 1 percent rise lacked statistical significance.

What about pregnant women who can’t get the vaccine?

antibodies, baby protection, FDA, CDC, MundoNOW
PHOTO: Shutterstock

Conversely, for pregnant women ineligible for the RSV vaccine, there is an alternative involving the administration of pre-made antibodies.

As mentioned earlier, Beyfortus is a monoclonal antibody approved for usage in infants up to eight months old.

Administered via a single injection of laboratory-crafted human antibodies, it extends protection against various illnesses.

These illnesses include bronchiolitis and pneumonia — both stemming from the respiratory syncytial virus (RSV).

How effective are the vaccine and monoclonal antibodies in preventing RSV in infants?

RSV vaccine pregnant women, risks, clinical trial, protection, MundoNOW
PHOTO: Shutterstock

Ultimately, both the maternal vaccine and the monoclonal antibody have shown efficacy in mitigating the risk of severe RSV-related illnesses.

According to The Associated Press, clinical trials indicate that the vaccine offers protection for up to six months.

On the other hand, the monoclonal antibody provides protection until the age of five months.

To maximize efficacy, the vaccine should be administered a minimum of 14 days prior to the anticipated birth, or even earlier if feasible, to optimize infant protection.

Etiquetas: ,
Related post
Regresar al Inicio